Efg Asset Management (North America) Corp. Acadia Pharmaceuticals Inc Transaction History

Efg Asset Management (North America) Corp.

  • $585 Million
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 25, 2024
BUY
$14.62 - $18.42 $5,321 - $6,704
364 Added 0.48%
75,748 $1.23 Million
Q1 2024

May 13, 2024
BUY
$17.79 - $30.86 $505,324 - $876,578
28,405 Added 60.46%
75,384 $1.39 Million
Q4 2023

Feb 08, 2024
BUY
$20.78 - $31.77 $147,496 - $225,503
7,098 Added 17.8%
46,979 $1.47 Million
Q3 2023

Nov 02, 2023
BUY
$20.84 - $33.47 $831,120 - $1.33 Million
39,881 New
39,881 $831,000

Others Institutions Holding ACAD

# of Institutions
279
Shares Held
156M
Call Options Held
901K
Put Options Held
314K
View Full List

About ACADIA PHARMACEUTICALS INC

ACAD Quotes by TradingView
  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.76B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Efg Asset Management (North America) Corp. Portfolio

Follow Efg Asset Management (North America) Corp. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Efg Asset Management (North America) Corp., based on Form 13F filings with the SEC.

News

Stay updated on Efg Asset Management (North America) Corp. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email